In prostate cancer models, it was shown that dutasteride synergistically suppresses tumor cell proliferation when combined with enzalutamide (a new generation AR antagonist that is more potent than bicalutamide).24 Therefore, combining dutasteride with ADT is a rational approach for future clinical trials in AR‐positive SDC, especially in a translational setting in which the use of SRD5A1 expression levels and/or AR pathway activity scores as predictive biomarkers are confirmed, preferably on metastatic tissue. Here, AR is linked to neoplasm.